Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
| Autor: | Aaron Polliack, Tamar Tadmor, Brunangelo Falini, James B. Johnston, Judit Demeter, Xavier Troussard, Jae-Hyun Park, Daniel Catovsky, Omar Abdel-Wahab, Alessandro Gozzetti, Versha Banerji, Alan Saven, Monica Else, John F. Seymour, James S. Blachly, Robert J. Kreitman, Constantine S. Tam, Clive S. Zent, Francesco Lauria, Kanti R. Rai, Emili Montserrat, Francesco Forconi, Michael R. Grever, Leslie A. Andritsos, Jacqueline C. Barrientos, Martin S. Tallman, Claire Dearden, Graeme R. Quest, Anthony D. Ho, Eric H. Kraut, Loree Larratt, Gunnar Juliusson, Enrico Tiacci, Sameer A. Parikh, Tadeusz Robak, Timothy G. Call, Pier Luigi Zinzani, Farhad Ravandi, Jeffrey A. Jones, Gerard Lozanski, Thorsten Zenz |
|---|---|
| Přispěvatelé: | Normandie, Université, Ohio State University [Columbus] (OSU), Memorial Sloane Kettering Cancer Center [New York], University of Manitoba [Winnipeg], Hofstra University [Hempstead], Mayo Clinic [Rochester], The institute of cancer research [London], Royal Marsden NHS Foundation Trust, Semmelweis University of Medicine [Budapest], University of Southampton, Azienda Ospedaliera Universitaria Senese, University of Heidelberg, Medical Faculty, Skane University Hospital [Lund], National Institutes of Health [Bethesda] (NIH), University of Alberta, University of Barcelona, The Hebrew University Hadassah Medical School, University Health Network, The University of Texas M.D. Anderson Cancer Center [Houston], Medical University of Łódź (MUL), Scripps Clinic [San Diego, CA, USA], University of Melbourne, Technion - Israel Institute of Technology [Haifa], Università degli Studi di Perugia = University of Perugia (UNIPG), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Rochester Medical Center (URMC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), University of Bologna/Università di Bologna, Università degli Studi di Perugia (UNIPG), University of Bologna, Grever, Michael R, Abdel-Wahab, Omar, Andritsos, Leslie A., Banerji, Versha, Barrientos, Jacqueline, Blachly, James S., Call, Timothy G., Catovsky, Daniel, Dearden, Claire, Demeter, Judit, Else, Monica, Forconi, Francesco, Gozzetti, Alessandro, Ho, Anthony D., Johnston, James B., Jones, Jeffrey, Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Larratt, Loree, Lauria, Francesco, Lozanski, Gerard, Montserrat, Emili, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme R., Rai, Kanti R., Ravandi, Farhad, Robak, Tadeusz, Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine, Tiacci, Enrico, Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, Falini, Brunangelo |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Neoplasm Residual Hairy Cell Immunology Antineoplastic Agents Review Article Disease Biochemistry [SDU] Sciences of the Universe [physics] 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) medicine Humans Hairy cell leukemia Disease management (health) Intensive care medicine Leukemia Hairy Cell Leukemia business.industry Risk of infection Disease Management Hematology Cell Biology Cladribine Neoplasm Recurrence Local Pentostatin Treatment Outcome medicine.disease Minimal residual disease 3. Good health Clinical trial Clinical research Neoplasm Recurrence Local [SDU]Sciences of the Universe [physics] 030220 oncology & carcinogenesis Residual Neoplasm business 030215 immunology |
| Zdroj: | Blood Blood, 2017, 129 (5), pp.553-560. ⟨10.1182/blood-2016-01-689422⟩ Blood, American Society of Hematology, 2017, 129 (5), pp.553-560. ⟨10.1182/blood-2016-01-689422⟩ |
| ISSN: | 0006-4971 1528-0020 |
| DOI: | 10.1182/blood-2016-01-689422⟩ |
| Popis: | Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|